A long-lasting growth hormone booster. The DAC (Drug Affinity Complex) part keeps it active in your body much longer than similar peptides, giving you a steady, sustained rise in growth hormone for better muscle growth, fat loss, and recovery.
What to Expect
Week 1–2
Increased deep sleep quality. Mild water retention. Slight increase in appetite. GH/IGF-1 levels begin rising steadily.
Week 3–6
Improved recovery from exercise. Fat loss begins, especially visceral fat. Skin quality improves. Sustained IGF-1 elevation measurable on labs.
Week 8+
Significant body recomposition — less fat, more lean mass. Joint and connective tissue repair. Improved sleep architecture. Hair and nail growth.
Common Side Effects
Scientific Overview
CJC-1295 with Drug Affinity Complex (DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), modified at positions 2, 8, 15, and 27 with a maleimidopropionic acid linker conjugated to lysine. The DAC modification enables covalent binding to serum albumin, extending the half-life from ~7 minutes (native GHRH) to 5–8 days. It stimulates pituitary somatotroph cells via the GHRH receptor, producing sustained elevation of GH pulsatility and IGF-1 levels without disrupting the natural GH secretory pattern.
Dosing
2 mg subq once a week. Cycle for 8-12 weeks.
Practical Guide
Reconstitution
Mix 2mg vial with 1-2mL BAC water. Typical dose is 0.5-1mg per injection.
Storage
Refrigerate after reconstitution. Use within 30 days. Avoid shaking — swirl gently.
Injection Sites
Subcutaneous injection with 29-31g insulin syringe. Due to long half-life, only inject 1-2 times per week.
Timing
Inject before bed to synergize with natural nighttime GH pulse. Avoid injecting near meals or post-workout carbs.
Food
Inject on empty stomach for optimal GH release. Avoid eating 30 minutes before and after injection. High-fat meals blunt GH release.
Benefit Profile
Medical Considerations
Contraindications
- ✕Active cancer or pituitary tumors
- ✕Diabetic retinopathy
- ✕Pregnancy/nursing
- ✕Active acromegaly
- ✕Uncontrolled diabetes
Drug Interactions
Recommended Monitoring
- →IGF-1 levels every 3 months
- →Fasting glucose and HbA1c every 3 months
- →Monitor for carpal tunnel symptoms
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.